Toronto Stock Exchange Symbol: MS
EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.
This was the third of several regularly scheduled reviews by the DSMB
that will occur over the duration of the trial. The purpose of the DSMB is
to provide objective, independent safety monitoring of the trial.
The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized,
double-blind study that has completed recruitment of approximately 510
patients at 68 clinical sites who will be administered either dirucotide
(MBP8298) or placebo intravenously every six months for a period of two
years. The primary clinical endpoint for the trial is defined as a
statistically and clinically significant increase in the time to
progression of the disease as measured by the Expanded Disability Status
Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes
(up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, dirucotide (MBP8298), is for the treatment of multiple
sclerosis and is being evaluated in two pivotal phase III clinical trials
for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and
MAESTRO-03 in the United States. It additionally is being evaluated for
relapsing remitting MS patients in a Phase II trial in Europe entitled
MINDSET-01. In December 2007
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved